Back

The effect of dapagliflozin on the microvascular endothelial cell function and metabolism in patients with heart failure: a preliminary report

17 May 2025 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: Vericiguat, SGLT2 inhibitors and implementation Pharmacotherapy HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Miss Maria Tarnawska

Medical University of Gdansk, Gdansk (Poland)

6 More presentations in this session

Presentation thumbnail
A placebo-correcetd effect of the initial eGFR decline following SGLT-2 inhibitor initiation: a systematic review and meta-analysis
Doctor S. Urban (Lubin, PL)
Abstract Slides Video
Presentation thumbnail
Scarred for life - outcomes of ischaemic and non-ischaemic cardiomyopathy after heart failure optimisation
Doctor O. Graham (Craigavon, GB)
Abstract Slides Video
Presentation thumbnail
Estimated multinational budget impact of empagliflozin for heart failure patients with full spectrum of left ventriclular ejection fraction
Doctor E. Kim (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
Vericiguat in a real-world heart failure population: a single-centre experience
Mr C. Palacios-Castello (Seville, ES)
Abstract Slides Video
Presentation thumbnail
Quantifying the burden of potentially inappropriate prescribed medicines among people hospitalised with heart failure in Australia: a comparison with ESC recommendations
Associate Professor M. Falster (Sydney, AU)
Abstract Slides Video

Access the full session

Session thumbnail
Vericiguat, SGLT2 inhibitors and implementation

The Event

Event poster

Heart Failure 2025

17 May - 20 May 2025
You may be interested in
thumbnail
Congress Presentation
Twelve-months treatment with dapagliflozin improves endothelial glycocalyx and cardiovascular function in patients with type 1 diabetes mellitus
thumbnail
Congress Presentation
Dapagliflozin effect on cardiopulmonary function, reverse cardiac remodelling and biomarkers in a cohort of HFrEF patients
thumbnail
Congress Presentation
Dapaglifozin in advanced heart failure patients : effects on congestion, NTproBNP and cardiorenal outcome

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources